Brain Tumour Survival Rates

Nusrat Ghani Excerpts

Monday 9th February 2026 Commons Chamber

[Madam Deputy Speaker (Ms Nusrat Ghani)]

I call Dame Siobhain McDonagh, who will speak for up to 15 minutes.

--- Later in debate ---

[Peter Prinsley (Bury St Edmunds and Stowmarket) (Lab)]

It is an honour to speak in this debate. I thank my hon. Friend the Member for Mitcham and Morden (Dame Siobhain McDonagh) and the hon. Member for Witney (Charlie Maynard) for securing it. We have heard many fine and very heartfelt speeches this evening, particularly those recounting personal stories about Members’ families.

Our new cancer strategy was announced last week. Sadly, political events of the past few days have somewhat submerged its importance, but we should be talking about it, as it is much the most important political development as far as I am concerned. We have seen little progress in brain tumour care—that is the truth of the matter. Those tumours are devastating; they rob victims of years of life, and wreck families. I have seen such patients over the years, and I can say that diagnosis may be very difficult, even with the help of hindsight.

An average general practitioner will see a new brain tumour once every seven years, but they will see thousands of patients in that time, so it is not surprising that the tumours are difficult to diagnose. I hear that a patient with a brain tumour will often have visited their general practitioner five or six times before a diagnosis is made. We must do what we can to raise awareness. In ear, nose, and throat care—which, as Members may know, is my specialty—we see a condition called acoustic neuroma. It is a brain tumour on the nerves that lie between the ear and the brain—the balance nerves. Such tumours are rare, even in ear, nose and throat clinics. I would see only a handful of them each year. Sometimes they present with a little hearing loss in one ear, or with just a little ringing. Sometimes they present incidentally.

Some of the other brain tumours we see in the ENT world are very rare. One that sits in the roof of the nose —an olfactory neuroblastoma—is so rare that I probably saw fewer than six or seven cases throughout my career, yet it presents with a loss of sense of smell, which is a very common problem for people who come to see ear, nose and throat surgeons or general practitioners. We must not deceive ourselves that we are dealing with an easy condition, for this is a difficult one.

I believe that we must support research into these mysterious diseases. As I have said before in this Chamber, this country is desperately short of medical researchers and clinical academics. Many of our clinical academics are getting towards the end of their careers, and we are not doing enough to recruit new academics in the early part of theirs. I would like us to think about what policies we might develop to encourage that—this is a political problem. My hon. Friend the Member for Mitcham and Morden said that given we have made so little progress, we must be content with the status quo. I beg to differ; we are not content with the status quo, and that is why we are all here this evening to discuss this matter.

We know that this is a promising time for some areas of medical research. Genetic research, for instance, is now becoming very important. I am not sure that whole genome sequencing, if that were available for everybody, would solve the problem, but it is the way we are going. Before I came to this place, I was involved in research into a rare ear disease called cholesteatoma. We did genetic research on that—genome sequencing—and we were able to identify some of the genes that probably cause the condition, but that does not make it any easier for us to prevent it, for we cannot choose our genetic code.

The problem with brain tumours is that they are deep-seated and inaccessible. We cannot see them or feel them, which is why curative approaches are so elusive. We can debate this in the Chamber until the cows come home, but that debate will not bring the cure, so we must decide what politically we can do to help. I welcome the £32 million boost to brain cancer research, and our new approach to clinical trials. I thank my hon. Friend the Member for Edinburgh South West (Dr Arthur) for his Rare Cancers Bill, and I congratulate him on getting it to advance so far. Like me, he is a new Member of Parliament, and I am in awe that you have managed—

[Madam Deputy Speaker (Ms Nusrat Ghani)]

He has managed—not “you”.

[Peter Prinsley]

Yes, I am in awe that my hon. Friend has managed to achieve so much; you see, Madam Deputy Speaker, I am a new Member of Parliament!

Let us encourage clinical trials, for as Lord Vallance has said:

“Clinical trials are the route by which promising research can be turned into treatments”,

which will save lives.